NCT06516029View on ClinicalTrials.gov

Real-World Evaluation of Patient Characteristics and Treatment Patterns Among Patients With CML-CP Treated With Asciminib

CompletedOBSERVATIONAL
Enrollment

111

Participants

Timeline

Start Date

April 21, 2023

Primary Completion Date

October 2, 2023

Study Completion Date

October 2, 2023

Conditions
Chronic Myeloid Leukemia, Chronic Phase
Trial Locations (1)

07936

Novartis Pharmaceuticals, East Hanover

Sponsors

Lead Sponsor

Novartis
All Listed Sponsors
lead

Novartis

INDUSTRY